Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 Plus Lenvatinib and TACE in Unresectable HCC
NCT05319431Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc. Primary endpoint: Progression-free survival up to 2 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05319431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319431.